NCT02260687View on ClinicalTrials.gov

Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization

CompletedOBSERVATIONAL

Enrollment

353

Participants

Timeline

Start Date

December 5, 2014

Primary Completion Date

April 2, 2018

Study Completion Date

August 22, 2018

Conditions

Choroidal Neovascularization

Interventions

DRUG

Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Administration by intravitreal injection

Trial Locations (1)

Unknown

Multiple Locations

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Bayer

INDUSTRY